HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients
Year: 2018
Type: article
Study design: Observational Study
Abstract: Brain metastases from colorectal cancer (CRC) are a rare but increasing event as patients survive longer. While HER2 gene amplification in breast cancer is well described and known to increase risk of brain metastases [1], information in CRC patients with brain metastases is lacking. A multi-centre phase II trial has shown that HER2-directed therapies are efficacious in HER2 positive (HER2+) stage IV CRC without brain metastases [2]. If HER2 is enriched in CRC patients with brain metastases, it may provide a possible therapeutic target.
Source: Annals of Oncology
Authors: R.Y.C. Tan, M.D. Camat, M. Ng, T.H. Lim, A.S.T. Lim, K.H. Lim, I.B.H. Tan
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2806959744
